Optimal efficacy and safety of humanized anti-scg3 antibody to alleviate oxygen-induced retinopathy

Ye He, Hong Tian, Chang Dai, Rong Wen, Xiaorong Li, Keith A. Webster, Wei Li

Research output: Contribution to journalArticlepeer-review


The retinopathy of prematurity (ROP), a neovascular retinal disorder presenting in pre-mature infants, is the leading causes of blindness in children. Currently, there is no approved drug therapy for ROP in the U.S., highlighting the urgent unmet clinical need for a novel therapeutic to treat the disease. Secretogranin III (Scg3) was recently identified as a disease-selective angiogenic factor, and Scg3-neutralizing monoclonal antibodies were reported to alleviate pathological retinal neovascularization in mouse models. In this study, we characterized the efficacy and safety of a full-length humanized anti-Scg3 antibody (hAb) to ameliorate retinal pathology in oxygen-induced retinopathy (OIR) mice, a surrogate model of ROP, by implementing histological and functional analyses. Our results demonstrate that the anti-Scg3 hAb outperforms the vascular endothelial growth factor inhibitor aflibercept in terms of efficacy and safety to treat OIR mice. Our findings support the development of anti-Scg3 hAb for clinical application.

Original languageEnglish (US)
Article number350
JournalInternational journal of molecular sciences
Issue number1
StatePublished - Jan 1 2022
Externally publishedYes


  • Aflibercept
  • Anti-Scg3 therapy
  • Anti-VEGF
  • Anti-angiogenic therapy
  • Humanized antibody
  • Oxygen-induced retinopathy
  • Retinopathy of prematurity
  • Safety
  • Scg3
  • Secretogranin III

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'Optimal efficacy and safety of humanized anti-scg3 antibody to alleviate oxygen-induced retinopathy'. Together they form a unique fingerprint.

Cite this